Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes

IMPORTANCE: Evidence suggests that patients with human epidermal growth factor receptor 2–positive (ERBB2+ [formerly HER2+]) metastatic breast cancer (MBC) have different clinical characteristics and outcomes according to their hormone receptor (HR) status. The place of endocrine therapy (ET) for pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Carausu, Marcela, Carton, Matthieu, Diéras, Véronique, Petit, Thierry, Guiu, Séverine, Gonçalves, Anthony, Augereau, Paule, Ferrero, Jean Marc, Levy, Christelle, Ung, Mony, Desmoulins, Isabelle, Debled, Marc, Bachelot, Thomas, Pistilli, Barbara, Frenel, Jean-Sébastien, Mailliez, Audrey, Chevrot, Michaël, Cabel, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856509/
https://www.ncbi.nlm.nih.gov/pubmed/36520434
http://dx.doi.org/10.1001/jamanetworkopen.2022.47154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856509/
https://www.ncbi.nlm.nih.gov/pubmed/36520434
http://dx.doi.org/10.1001/jamanetworkopen.2022.47154

Ejemplares similares